Arteriosan

Quick links to important sections

Arteriosan

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Arteriosan

Property Description
Active ingredient Amlodipine (as besilate salt)
Form Oral tablet
Pharmacological class Dihydropyridine Calcium Channel Blocker (CCB)
Common purpose Management of high blood pressure and angina
Origin Synthetic compound

What Type of Medicine Is Arteriosan?

Arteriosan is a prescription cardiovascular agent primarily used to manage blood pressure and specific coronary conditions, belonging to the therapeutic category known as Calcium Channel Blockers (CCBs). Its core function is defined by its active ingredient, Amlodipine (INN), a synthetic compound specifically classified as a Dihydropyridine calcium channel blocker. The Amlodipine molecule is clinically recognized for its long-acting profile, which helps maintain consistent blood pressure control over a 24-hour period.

This type of medication differs fundamentally from other classes, such as Beta-blockers, as its mechanism is geared more toward reducing peripheral vascular resistance through vasodilation. Amlodipine is characterized as a highly effective and generally well-tolerated antihypertensive agent in clinical practice.


Composition, Origin, and Form of Arteriosan

The composition of Arteriosan is based on the single active ingredient Amlodipine, typically utilized in its chemically stable salt form, Amlodipine besilate, formulated as an oral tablet. Being a synthetic compound, it is manufactured using chemical processes, defining it as a product without natural botanical components.

Amlodipine produces its antihypertensive action primarily by acting on the vascular smooth muscle. This presentation as an oral tablet is essential for convenient, long-term therapeutic protocols, facilitating administration via the oral route.


Arteriosan's General Purpose as an Antihypertensive

The general therapeutic purpose of Arteriosan is to facilitate the relaxation of blood vessels, which serves to lower dangerously high blood pressure (hypertension). By acting as a Calcium Channel Blocker, the medicine allows the walls of the arteries to relax and widen, easing the flow of blood throughout the circulatory system. This reduction in resistance lowers the overall workload and strain on the heart muscle. Consequently, this action not only manages systemic pressure but also improves the supply of oxygen-rich blood to the heart itself, providing a general benefit in relieving symptoms associated with angina pectoris.

Regulatory References

  1. Amlodipine: MedlinePlus Drug Information
  2. European Medicines Agency (EMA) Amlodipine EPAR

What side effects are possible with Arteriosan?

Possible Side Effects and Safety Information for Arteriosan

Like all prescription medications, Arteriosan can cause side effects. These are typically categorized by frequency based on governmental regulatory safety documents, which helps define the drug’s overall risk profile.

Classification Common Side Effects (Occur in ge 1/100 to < 1/10)
Gastrointestinal Nausea, indigestion, constipation, diarrhea.
Nervous System Headache, dizziness.
General Mild muscle discomfort or pain (myalgia).

Serious and Clinically Significant Adverse Reactions

The most serious, though rare (less than 1 in 10,000 users), risks associated with Arteriosan involve severe muscle damage and effects on the liver. These are documented by regulatory authorities as requiring immediate medical attention.

  • Rhabdomyolysis: This is a rare, severe form of muscle breakdown that can lead to kidney failure and is considered a critical safety concern. The risk of this reaction may increase with higher doses or when Arteriosan is taken alongside certain other medicines.
  • Hepatotoxicity: Liver enzyme elevations can occur. Persistent, unexplained elevations or the development of active liver disease are formal contraindications to using the medicine.

Safety Monitoring and Restrictions

Official labeling requires specific safety measures for Arteriosan:

  1. Contraindications: Arteriosan is formally contraindicated in patients with active liver disease.
  2. Required Monitoring: Liver function tests (LFTs) and creatine kinase (CK) levels are typically monitored prior to initiating treatment and periodically thereafter to detect potential hepatotoxicity or muscle effects early.
  3. Population Considerations: Use in individuals with severe pre-existing renal impairment is restricted, and caution is advised for those with hepatic disease.

The overall safety profile indicates that while common side effects are generally mild and self-limiting, the potential for rare, serious complications requires strict adherence to mandatory laboratory monitoring and formal safety restrictions defined in the official regulatory documentation.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information details the officially documented manifestations and required emergency actions for an overdose of Arteriosan (Amlodipine), strictly based on governmental regulatory sources.

Documented Overdose Manifestations

Overdose is primarily characterized by effects related to excessive dilation of blood vessels, most commonly leading to marked hypotension (severely low blood pressure) and excessive peripheral vasodilation. A compensatory reflex tachycardia (rapid heart rate), dizziness, and fainting are also officially documented.

Severe Outcomes and Required Actions

The primary documented severe risk is that prolonged systemic hypotension may progress to shock and potentially death. Because of this risk, immediate medical help is mandatory:

  • Seek Immediate Emergency Medical Help: Individuals must contact a doctor, pharmacist, hospital emergency department, or a Poison Control Centre immediately upon suspected overdose.
  • Call Emergency Services: For life-threatening symptoms such as collapse, seizure, trouble breathing, or the inability to be awakened, immediate contact with emergency services is required.

Official Management Notes

Regulatory documents specify that management requires active cardiac and respiratory monitoring and frequent blood pressure measurements. Treatment involves supportive measures, including the administration of activated charcoal and the potential use of vasopressors for severe, unresponsive hypotension. Due to the high protein binding of Amlodipine, hemodialysis is not likely to be beneficial.

Therapeutic Uses of Arteriosan

Arteriosan (amlodipine) is commonly used to provide therapeutic support across relevant cardiovascular domains. Its use may play a role in managing risks associated with chronic conditions and is relevant for easing symptoms related to systemic imbalance. This medication is applied in clinical settings that involve sustained symptomatic support.

Arteriosan is commonly used to help with managing symptom clusters associated with two primary conditions: systemic hypertension and the recurrent or episodic manifestations of chest discomfort from angina pectoris.

In the context of hypertension, the patient-oriented benefit helps address symptoms that create noticeable physiological strain. This assists with maintaining functional stability. Regarding angina, the medication is applied across domains where additional symptomatic support is needed to address discomfort. This use contributes to improved comfort during symptomatic periods and may help patients cope more steadily with symptom fluctuations by easing distress.

“The medication may be part of symptomatic management that supports the reduction of associated cardiovascular risks.”


Quick Fact: Symptomatic Support
Arteriosan assists with managing symptom clusters associated with episodic changes of chest pain (angina) associated with reduced oxygen availability.

Regulatory References

  1. NIH MedlinePlus overview of Amlodipine

Eligibility and Restrictions for Use

Who Can and Cannot Use Arteriosan? (Population Eligibility)

Contraindicated Populations

Arteriosan (amlodipine) is strictly contraindicated for any individual with a documented history of hypersensitivity or allergic reaction to amlodipine or to other calcium channel blockers of the dihydropyridine class. Use is also restricted in patients experiencing severe cardiovascular events such as cardiogenic shock or severe hypotension.

Age-Group Eligibility

The medicine is approved for use in adults for both high blood pressure and angina. In the pediatric population, it is officially approved only for the treatment of hypertension in children and adolescents aged 6 years to 17 years. The effect and safety profile for children under the age of 6 is currently not established by regulatory documents. Older adults may require a lower starting dose due to potential changes in clearance.

Conditional Use and Restrictions

Use is permitted under caution in certain populations. Patients with severe hepatic impairment require slow, careful introduction of the medicine due to altered metabolism. For patients with severe obstructive coronary artery disease, the official labeling includes a specific warning regarding the potential for worsening angina or acute myocardial infarction upon treatment initiation. For renal impairment, the normal dosage is recommended.

Pregnancy and Lactation Status

Safety in human pregnancy is not established; use is generally restricted to situations where the potential benefit justifies the risk. The medicine is excreted in human milk, and regulators advise that mothers discontinue breastfeeding or discontinue the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Arteriosan (Amlodipine) based primarily on documented effects on metabolic pathways and additive pharmacodynamic actions.

Drug–Drug and Drug–Substance Interactions

Classification Interacting Entity Regulatory Statement on Outcome
Formal Restriction Dantrolene (infusion) Co-administration must be avoided in patients susceptible to malignant hyperthermia due to the risk of hyperkalemia.
Metabolic (Exposure) Strong/Moderate CYP3A4 Inhibitors (e.g., Clarithromycin) Causes a significant increase in amlodipine exposure (AUC/Cmax), resulting in an increased risk of hypotension.
Exposure Limitation Simvastatin (Statin) The maximum daily dose of Simvastatin must be limited to 20 mg due to a documented increase in its systemic exposure (AUC).
Pharmacodynamic Other Antihypertensive Agents Co-administration results in additive blood pressure lowering effects.
Drug–Food/Herbal Grapefruit / Grapefruit Juice Consumption is not recommended as it may increase amlodipine bioavailability and resultant effects.
Drug–Substance Alcohol (Ethanol) May have additive effects in lowering blood pressure when consumed.

Population-Specific Interaction Notes

Official labeling documents require caution for patients with hepatic impairment (liver disease). This is due to decreased clearance of Amlodipine, which leads to a documented increase in systemic exposure (AUC is increased by 40%–60%) in this population.

Mechanism of Action

Blocking Calcium Channels to Modulate Vascular Tone

Arteriosan exerts its primary mechanism of action by functioning as an inhibitor of L-type voltage-gated calcium channels located on the surface of vascular smooth muscle cells. This inhibitory action interrupts the necessary influx of extracellular calcium ions into the cell's interior.

By suppressing the entry of calcium, the drug directly disrupts the calcium-dependent contraction pathway within the arterial walls. This molecular interference leads to the relaxation and widening (vasodilation) of the arteries, resulting in a reduction of the internal resistance encountered by the blood flow.

The widespread relaxation across the peripheral arterial network causes a decrease in systemic vascular resistance (SVR). This systemic physiological adjustment decreases the mechanical load placed on the heart (afterload), thereby regulating the blood flow dynamics within the circulatory system.

Dosage and Administration Information

Arteriosan is administered orally and is typically prescribed as a component of long-term therapy for chronic conditions. The medicine is taken once daily, and it may be taken either with or without food. To maintain consistent systemic concentration, it is generally advised to establish a routine of taking the oral tablet at the same time each day.

For most adults initiating treatment for either hypertension or angina, the initial standard dose is 5 mg once daily. The maximum daily dose is 10 mg. Any subsequent adjustment to the dose should generally be performed over a gradual period, with 7 to 14 days suggested between increases to fully assess the body's response.

Specific usage principles apply to certain populations. Older adults and individuals with hepatic impairment (liver issues) should typically initiate treatment at a lower daily dose of 2.5 mg. For pediatric patients aged 6 to 17 years being treated for hypertension, the starting dose is 2.5 mg, with a maximum dose of 5 mg once daily. Notably, no initial dose adjustment is required for patients with renal impairment. The tablets should be swallowed whole. A critical administration constraint is the avoidance of grapefruit or grapefruit juice, as these can affect the medication’s profile.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Arteriosan

The clinical evidence for Arteriosan, which contains the active ingredient amlodipine, is drawn from comprehensive research, primarily consisting of Randomized Controlled Trials (RCTs) and regulatory-reviewed studies. The research describes studies evaluating amlodipine in two main areas: high blood pressure and conditions characterized by episodic or acute changes related to chest discomfort. The findings describe patterns observed in large patient populations, helping to contextualize what is known and what remains under investigation.


Research Evidence for Managing High Blood Pressure

The research for amlodipine in high blood pressure (systemic hypertension) includes comprehensive studies. Research examined the use of amlodipine both alone and in combination with other therapeutic agents across diverse patient groups. Studies monitored key physiological outcomes, mainly looking at changes in systolic and diastolic blood pressure (BP) measurements. Furthermore, long-term observational studies were conducted to track outcomes related to systemic or functional imbalance, monitoring the frequency of Major Adverse Cardiovascular Events (MACE), such as stroke, myocardial infarction (heart attack), and heart failure hospitalization.

Research Evidence for Managing Angina Pectoris

Amlodipine was studied for both chronic stable angina (chest discomfort related to exertion) and vasospastic angina (sometimes called Prinzmetal’s or Variant angina), which are conditions characterized by fluctuating or episodic manifestations of physical discomfort. In these trials, researchers explored how symptoms change over time by monitoring patient-reported outcomes describing perceived discomfort. Findings indicate that patterns of change were measured in the reported frequency of chest discomfort episodes, and studies monitored shifts in patient functional capacity.

Areas of Research Uncertainty and Gaps

While evidence in core adult populations is robust, long-term effects are not fully established for all possible uses and patient profiles. Data for certain groups remain insufficient, particularly for rare or highly complex patient profiles. Research continues to explore patterns observed in all cases of very difficult-to-control or refractory hypertension.

Key Studies & References Amlodipine: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Arteriosan (FAQ)

Q: What is the main difference between Arteriosan and other common blood pressure medicines?

According to official documents, Arteriosan is classified as a Dihydropyridine Calcium Channel Blocker (CCB). This type of medicine works by blocking the entry of calcium ions into the artery walls, causing them to relax and widen. This specific mechanism of action is distinct from other therapeutic classes used to manage blood pressure.

Q: Do I need to change my diet while taking Arteriosan?

Official labeling states the medicine can be taken either with or without food. However, the use of this medicine is generally part of a comprehensive program for cardiovascular risk management. This full program often includes general guidance on diet and limited sodium intake.

Q: What are the most frequently reported mild side effects of Arteriosan?

Based on regulatory safety data from clinical trials, the most frequently reported mild side effects include swelling of the legs or ankles, headache, and fatigue. Other common reports include dizziness, nausea, and feeling sleepy. These common effects are described in the official product information.

Q: What is the risk of a serious allergic reaction to Arteriosan?

While all medicines carry a risk of allergic reactions, official documents advise seeking immediate medical attention if an individual experiences signs of a serious reaction. Such signs may include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat, as described in regulatory warnings.

Q: What are the main findings from the pivotal clinical trials for Arteriosan?

Research evidence described in official documents supports the drug's use in lowering blood pressure. The main goal of the trials was to show that this action helps reduce the risk of serious cardiovascular events, such as a nonfatal heart attack (myocardial infarction) or stroke.

Q: Is it common to feel tired when starting Arteriosan?

Yes, feeling tired or experiencing sleepiness is listed as a common adverse effect in official documents. This side effect is particularly noted to be more frequent when a person first begins treatment with the medicine.

Q: What happens if I stop taking Arteriosan suddenly?

Patients are advised not to stop taking the medicine without first consulting their healthcare provider. Official warnings state that for individuals with severe obstructive coronary artery disease, abrupt discontinuation can lead to a worsening of angina (chest pain) or even an acute heart attack.

Q: Does Arteriosan affect fertility or reproductive health?

Nonclinical toxicology studies have been conducted regarding potential effects on fertility. The findings from these types of animal studies are described in the official prescribing information for the drug.

Q: How long does it usually take to notice the effects of Arteriosan?

After a single dose, official pharmacological data indicates the medicine begins to decrease blood pressure over approximately 4 to 8 hours. To achieve consistent control, consistent plasma levels (steady state) are generally reached after 7 to 8 days of consecutive daily dosing.

Q: What are the most common reasons doctors prescribe Arteriosan?

The medicine is approved by regulatory bodies for two main purposes, or indications. These are the treatment of high blood pressure (hypertension) and the symptomatic management of certain conditions related to coronary artery disease, such as chronic stable angina.

Q: Can Arteriosan be used by people over the age of 70?

Use in older adults is addressed in the official prescribing information. The guidance suggests that treatment should be initiated at the low end of the dose range, which is typically 2.5 mg once daily, due to potential changes in drug clearance in this population.

Q: Is Arteriosan considered a first-line treatment for its primary use?

Official labeling states the medicine may be used alone, which is known as monotherapy, or it may be used in combination with other therapeutic agents for the treatment of high blood pressure.

Q: Are there any specific foods or drinks that should be avoided with Arteriosan?

Yes, consumption of grapefruit or grapefruit juice is specifically not recommended in official documents. This is because these products may interact with the medication, potentially affecting its systemic profile.

Q: I missed a dose of Arteriosan, what is the general guidance on this?

Official guidance states that a missed dose should be taken as soon as an individual remembers. However, if more than 12 hours have passed since the scheduled time, the missed dose should be skipped entirely. The next dose should then be taken at the regularly scheduled time.

Q: Does Arteriosan cause weight gain or weight loss?

Changes in body weight are listed in official adverse reaction data. This includes reports of both weight gain and weight loss as possible effects experienced by people taking the medicine.

Q: Can Arteriosan affect sleep patterns?

Sleepiness is listed as a common side effect, especially when treatment begins. Disturbances in sleep patterns, such as insomnia, have also been noted in official reports.

Q: Is it true that Arteriosan is used for more than just high blood pressure?

Yes. The drug is indicated for the treatment of high blood pressure, but official documents also confirm its approval for the symptomatic treatment of certain conditions related to coronary artery disease, such as chronic stable angina.

Q: How does Arteriosan compare to lifestyle changes for heart health?

The medicine is officially described as being only one component of a complete treatment program. This comprehensive approach may also include non-pharmacological methods like diet, regular exercise, and weight control for overall heart health.

Q: Are there any long-term studies available about using Arteriosan?

Yes. The clinical evidence supporting the drug includes long-term clinical studies. These studies track outcomes over time, such as Major Adverse Cardiovascular Events (MACE), stroke, and heart attack risk.

Q: Does taking Arteriosan mean I have to get blood tests regularly?

Yes. Official safety information indicates that mandatory laboratory monitoring is typically required prior to and periodically during treatment. This monitoring commonly includes checking liver function tests (LFTs) and creatine kinase (CK) levels.

Q: Is there a generic version of Arteriosan available?

Yes. The active ingredient in this medicine, amlodipine, is available in generic form. It is also available in combination with other medicines under various brand names, as described in regulatory ingredient databases.

Q: What happens if I drink alcohol while taking Arteriosan?

Official drug interaction reports indicate that alcohol (ethanol) may have an additive effect in lowering blood pressure. This could increase the risk of side effects like dizziness, lightheadedness, or fainting.

Q: Are there special considerations for taking Arteriosan in hot weather?

Since the medicine can cause dizziness or lightheadedness, patients are advised in official patient information that these effects may be more likely to occur if they exercise or when the weather is hot.

Q: Can people with diabetes generally use Arteriosan?

The drug is often used as part of a comprehensive cardiovascular risk management plan, which includes diabetes management. There is no general contraindication for its use specifically in the diabetic population.

Q: Is Arteriosan safe to use with multivitamin supplements?

Official interaction reports indicate that taking the medicine with a multivitamin supplement that contains minerals may potentially decrease the medicine's effects.

Q: What is the official recommended course duration for Arteriosan?

Since this medicine is approved for the long-term management of chronic conditions, such as high blood pressure, continuous daily administration is generally necessary to maintain its therapeutic effect.

Q: Are there common signs that Arteriosan is not working effectively?

Worsening symptoms, such as an increase in the frequency or severity of angina (chest pain) or general discomfort, could be a sign that the medicine is not working as expected. This is noted in official patient warnings.

Q: Can taking Arteriosan affect driving or operating machinery?

Yes. Because the medicine can cause side effects like dizziness, tiredness, or sleepiness, official documents advise against driving or operating machinery until the individual knows how the medicine affects them.

Q: What is the typical age range of people who use Arteriosan?

The medicine is approved for adults for its main indications. It is also approved for the treatment of high blood pressure in children and adolescents aged 6 to 17 years, according to official prescribing information.

Q: Are there specific patient groups where Arteriosan is generally avoided?

Yes. Official safety documents state that use is restricted or contraindicated for patients with severe conditions, including severe hypotension, active liver disease, severe aortic stenosis, severe obstructive coronary artery disease, or cardiogenic shock.

Q: Why is it important to keep taking Arteriosan even if I feel fine?

For chronic conditions like high blood pressure, many people do not notice symptoms, and may feel normal. However, official patient counseling emphasizes the importance of continuous use as directed to control the condition and prevent more serious long-term complications, such as stroke or heart failure.

Q: Do official documents mention any effects of Arteriosan on mood or anxiety?

Anxiety is listed among the possible side effects that have been reported from post-marketing experience. This information is included in the adverse reaction sections of the official documents.

Q: Can Arteriosan be split or crushed?

Official labeling for the tablet form states that for certain pediatric dosing requirements, the tablet can be divided into equal doses. Final instructions regarding the handling of the tablet form are provided in the patient information leaflet.

Q: How does Arteriosan relate to kidney function over time?

Official studies on kidney function describe that therapeutic doses may lead to a decrease in renal vascular resistance and an increase in the glomerular filtration rate. Dosage is typically not adjusted for renal impairment.

Q: Are there special precautions for people with a history of heart rhythm issues?

Official warnings state that worsening angina or acute myocardial infarction can develop, particularly in patients with severe obstructive coronary artery disease. Additionally, heart palpitations and irregular heartbeat are reported as adverse reactions.

Q: What information is usually found in the patient information leaflet for Arteriosan?

Patient information leaflets typically contain required sections on the medicine's uses, contraindications, and how it should be taken. They also include detailed information on possible side effects, warnings about stopping the medicine, and effects on functional capacity, such as driving.

How should Arteriosan be stored and disposed of?

How to Store and Dispose of Arteriosan

Arteriosan (Amlodipine) must be stored according to specific regulatory requirements to maintain the tablet's stability.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature of 20 C to 25 C (68 F to 77 F), with permitted excursions [1].
Protection Must be kept in a dry place and in the original container, tightly closed [2].
Child Safety Keep the medication out of the reach of children [2].

Disposal Guidelines

Unused or expired Arteriosan must not be disposed of by flushing down the toilet or throwing into household trash [3]. The medicine should be discarded through an established medicine take-back program or by following guidelines provided by local waste authorities [3].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Arteriosan found in:

A-Z Index: